Jun 09, 2023 / 12:00PM GMT
Dietrich Stephan - NeuBase Therapeutics, Inc. - CEO, Founder, & Director
Good morning. My name is Dietrich Stephan. I'm the CEO of NeuBase Therapeutics.
Terry Horgan died eight days after being dosed with a CRISPR/Cas9 gene editor delivered with an adeno-associated virus. The cause of death was an acute innate inflammatory response. In January 2023, Acowin report estimated that 36% of all gene editing programs utilize viral mediated delivery. These viruses -- these immunogenic viruses deliver a gene that expresses a bacterial protein in a human being that performs the editing.
This bacterial protein, even if delivered without a virus, can also cause an immune response. These immune responses can be dangerous and limit the ability to re-dose the editors should durability or pharmacology waned.
NeuBase has developed a nuclease-free gene-editing technology that is not delivered using viral vectors to completely synthetic platform, and it is delivered via nanoparticles. We view the evolution of the gene-editing space as you can see on this slide. The first generation of editors
NeuBase Therapeutics Inc at Jefferies Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers